Ryan Savitz - 03 Feb 2026 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role: EVP, CFO & CBO
Signature: /s/ Adam Veness, as attorney-in-fact for Ryan Savitz
Issuer symbol: DNTH
Transactions as of: 03 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2026, 17:40:04 UTC
Previous filing: 05 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Savitz Ryan	EVP, CFO & CBO	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK	/s/ Adam Veness, as attorney-in-fact for Ryan Savitz	04 Feb 2026	0001992324

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNTH	Stock Option (Right to Buy)	Award	$0	+150,000		$0.000000	150,000	03 Feb 2026	Common Stock	150,000	$52.46	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.